Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 7/20 | 0.77 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.77 |
| ▸ | ATR | Q13535 | 11/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | ATRIP | Q8WXE1 | 3/20 | 0.55 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.52 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.49 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3095364 | 0.90 | PIK3CA (0.73) | MTORPIK3CAATRCYP2C9ATRIP | |
| SCHEMBL3083758 | 0.87 | PIK3CA (1.00) | MTORPIK3CAATRCYP2C9ATRIP | |
| SCHEMBL3095615 | 0.87 | PIK3CA (1.00) | MTORPIK3CAATRCYP2C9ATRIP | |
| SCHEMBL3076035 | 0.86 | PIK3CA (0.85) | MTORPIK3CAATRCYP2C9ATRIP | |
| SCHEMBL3081702 | 0.85 | PIK3CA (0.79) | MTORPIK3CAATRCYP2C9ATRIP | |
| SCHEMBL3085368 | 0.85 | PIK3CA (0.82) | MTORPIK3CAATRCYP2C9ATRIP | |
| SCHEMBL3093050 | 0.83 | MTOR (0.67) | MTORPIK3CAATRCYP2C9ATRIP | |
| SCHEMBL1271787 | 0.83 | MTOR (0.73) | MTORPIK3CAATRCYP2C9 | |
| SCHEMBL27812275 | 0.83 | MTOR (0.67) | MTORPIK3CAATRCYP2C9ATRIP | |
| SCHEMBL3093087 | 0.83 | PIK3CA (0.80) | MTORPIK3CAATRCYP2C9ATRIP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100227858-A1 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2010-09-09 | — | — | US | disclosed |
| US-20100227858-A1 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2010-09-09 | — | — | US | disclosed |
| US-20100227858-A1 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2010-09-09 | — | — | US | disclosed |
| CN-101801963-A | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases | ASTRAZENECA AB | 2010-08-11 | — | — | CN | disclosed |
| WO-2009007751-A2 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227858-A1 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | MTOR, PIK3CA, PIK3CD | MTOR 1/4885PIK3CA 2/4885ATR 706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.